Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product

Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product Diabetes cure: USFDA’s designation of Semglee (insulin glargine) as interchangeable with Lantus (insulin glargine of Sanofi) means that Semglee may now be substituted for the reference product at the pharmacy without the intervention of the prescriber.

from Moneycontrol Business News https://ift.tt/3f9mtIh
Posted by: at
Tags:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Start-up Street: Social justice and the start-up ecosystem

Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...